Ammendolia, I.; Sframeli, M.; Esposito, E.; Cardia, L.; Noto, A.; Currò, M.; Calapai, G.; De Pasquale, M.; Mannucci, C.; Calapai, F.
Adverse Reactions to the Orphan Drug Cerliponase Alfa in the Treatment of Neurolipofuscinosis Type 2 (CLN2). Pharmaceuticals 2024, 17, 1513.
https://doi.org/10.3390/ph17111513
AMA Style
Ammendolia I, Sframeli M, Esposito E, Cardia L, Noto A, Currò M, Calapai G, De Pasquale M, Mannucci C, Calapai F.
Adverse Reactions to the Orphan Drug Cerliponase Alfa in the Treatment of Neurolipofuscinosis Type 2 (CLN2). Pharmaceuticals. 2024; 17(11):1513.
https://doi.org/10.3390/ph17111513
Chicago/Turabian Style
Ammendolia, Ilaria, Maria Sframeli, Emanuela Esposito, Luigi Cardia, Alberto Noto, Mariaconcetta Currò, Gioacchino Calapai, Maria De Pasquale, Carmen Mannucci, and Fabrizio Calapai.
2024. "Adverse Reactions to the Orphan Drug Cerliponase Alfa in the Treatment of Neurolipofuscinosis Type 2 (CLN2)" Pharmaceuticals 17, no. 11: 1513.
https://doi.org/10.3390/ph17111513
APA Style
Ammendolia, I., Sframeli, M., Esposito, E., Cardia, L., Noto, A., Currò, M., Calapai, G., De Pasquale, M., Mannucci, C., & Calapai, F.
(2024). Adverse Reactions to the Orphan Drug Cerliponase Alfa in the Treatment of Neurolipofuscinosis Type 2 (CLN2). Pharmaceuticals, 17(11), 1513.
https://doi.org/10.3390/ph17111513
